Legend Biotech Corp
LEGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001801198
In the last 90 days, Legend Biotech Corp insiders filed 0 open-market purchases and 2 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $308.6K in total
- 2
- 13F holdersQ2 2026, +31 vs. previous quarter
- 219
- 13F valueReported value at the end of Q2 2026
- $2.98B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.03B
- +64.0% year over year
- Net income, FY2025
- -$296.8M
- No comparable prior period
- Free cash flow, FY2025
- -$128.8M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $296.8M (28.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.9M
- Shares sold short
- Change
- −2.00M
- −14.4% vs. previous
- Days to cover
- 6.29
- At average daily volume
Superinvestors holding LEGN, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Legend Biotech Corp on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
20.8%
Legend Biotech Corp's share of the portfolio
- Shares
- 5,984,550
- Value
- $172.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Legend Biotech Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 (view filing)4:04 PM ET | Sep 29 | 2 days | Sanders Corazon (Corsee) D.Director | SSale | −27.4K | $9.46 | −$258.9K | −34.2%52.7K after | |
| Sep 23, 2026 (view filing)4:15 PM ET | Sep 21 | 2 days | Santos Carlos EChief Financial Officer | SSale | −5.43K | $9.14 | −$49.6K | −27.6%14.2K after | |
| Jul 2, 2026 (view filing)4:05 PM ET | Jun 30 | 2 days | Casey Patrick JohnDirector | SSale | −6.00K | $14.80 | −$88.8K | −11.0%48.6K after | |
| Jun 29, 2026 (view filing) | Jun 25 | 4 days | Huang YingChief Executive Officer | SSale | −5.57K | $14.78 | −$82.3K | −2.2%241.9K after | |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Huang YingChief Executive Officer | SSale | −9.94K | $8.77 | −$87.1K | −3.9%247.4K after |
Top 10 13F holders, Q2 2026
See all 219 holdersThe largest institutional positions in Legend Biotech Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 29,093,899 | $840.2M | 0.04% | +3,397,159+13.2% | Added |
| Deerfield Management Company, L.P. (Series C) | 8,137,638 | $235.0M | 2.45% | +450,000+5.9% | Added |
| Suvretta Capital Management, LLC | 7,070,000 | $204.2M | 4.29% | −511,029−6.7% | Reduced |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 5,984,550 | $172.8M | 20.77% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,726,534 | $136.5M | 0.00% | +41,991+0.9% | Added |
| Westfield Capital Management Co LP | 4,430,063 | $127.9M | 0.42% | −1,333,412−23.1% | Reduced |
| Goldman Sachs Group Inc | 3,662,315 | $105.8M | 0.01% | +2,198,203+150.1% | Added |
| Point72 Asset Management, L.P. | 3,076,124 | $88.8M | 0.14% | −809,893−20.8% | Reduced |
| Kynam Capital Management, LP | 3,001,205 | $86.7M | 4.79% | +1,424,910+90.4% | Added |
| Assenagon Asset Management S.A. | 1,915,056 | $55.3M | 0.07% | +1,915,056 | New |
Holders of 5% or more of LEGN
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Legend Biotech Corp.